Navigation Links
AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove, Illinois
Date:9/13/2007

VALLEY FORGE, Pa., Sept. 13 /PRNewswire/ -- AmerisourceBergen Technology Group (ABTG), a unit of AmerisourceBergen Corporation, today celebrated the Grand Opening of its new facility in Buffalo Grove, Illinois, with a ribbon-cutting ceremony led by local dignitaries. The relocation of ABTG's operations and 180 employees from Vernon Hills, Illinois to the new facility will provide increased space for research and development as well as state-of-the-art product showrooms for its pharmacy automation systems.

"Our new Buffalo Grove facility reinforces our commitment to providing world-class pharmacy automation and continuously improving the quality of our products and services," said Pete Gilbert, Group Vice President of Operations for AmerisourceBergen Technology Group.

The ribbon-cutting ceremony participants included U.S. Representative Mark Kirk, State Representative Kathleen Ryg, and Buffalo Grove City Manager Bill Brimm.

The AmerisourceBergen Technology Group partners with pharmacies to improve efficiency through technology. Across all pharmacy markets and sizes, ABTG custom-designs solutions with advanced pharmacy automation, prescription fulfillment and distribution systems.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $64 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 11,500 people. AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information, go to http://www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes (including increased government regulation of the pharmaceutical supply channel); government enforcement initiatives (including (i) the imposition of increased obligations upon pharmaceutical distributors to detect and prevent suspicious orders of controlled substances (ii) the commencement of further administrative actions by the U. S. Drug Enforcement Administration seeking to suspend or revoke the license of any of the Company's distribution facilities to distribute controlled substances, or (iii) the commencement of any enforcement actions by any U.S. Attorney alleging violation of laws and regulations regarding diversion of controlled substances and suspicious order monitoring); changes in U.S. government policies (including reimbursement changes arising from federal legislation, including the Medicare Modernization Act and the Deficit Reduction Act of 2005); changes in regulatory or clinical medical guidelines and/or reimbursement practices for the pharmaceuticals we distribute; price inflation in branded pharmaceuticals and price deflation in generics; the inability of the Company to successfully complete any transaction that the Company may wish to pursue from time to time; fluctuations in market interest rates; operational or control issues arising from the Company's outsourcing of information technology activities; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar - Canadian dollar exchange rate and other foreign exchange rates; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; changes in tax legislation or adverse resolution of challenges to our tax positions; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the business of the Company generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2006 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.


'/>"/>
SOURCE AmerisourceBergen Technology Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vedic vibration technology- the new cure for arthritis
2. Biotechnology industry expected to grow into a three billion dollar industry by 2002
3. Biotechnology on the lead
4. New Technology In MRI Scan Help Test Brain Cancer Therapy
5. New technology to decipher neural connections dealing with heredity and environment
6. Emergence Of New Gene Scanning Technology In Disease Research
7. CoQ10 bioavailability increased by Nanotechnology
8. Developing a new vaccine using a new technology
9. Scientists Develop New Technology To Find About Human Ancestors’ Teet
10. T-waves to sweep over imaging technology
11. Nanotechnology Revolution To Be Spearheaded By European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a ... author, Sara Seymour, who lives in Lafayette, Indiana where she works in a daycare ... coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: ... by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, ... and poetry collections. , “I have been writing since high school and have ...
(Date:1/20/2017)... ... 20, 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring ... published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican ... Reverend Mark Hardy , “While sitting up in bed, I felt a pounding headache. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... introducing the Aerolib Learning Management System: an On-demand E-learning system for Clinical ... and Hospital Administration that is based on Aerolib`s successful education methodology of ...
(Date:1/19/2017)... ... 2017 , ... Wells Pharmacy Network announced the completion of ... pharmacy located in Ocala, Florida. , Meeting the Needs of a Growing ... States for high-quality human anti-aging and wellness compounded medications, Wells Pharmacy ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... analysis instruments and consumables for the medical and veterinary ... its financial results for the third quarter fiscal year ... at 4:15 p.m. ET on Thursday, January 26, 2017.  ... quarter fiscal year 2017 after the market closes on ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
Breaking Medicine Technology: